Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib-Reference-Cited by-同舟云学术

Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib

Published:2014-11-19 Issue:2 Volume:90 Page:105-108
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Latagliata Roberto¹,Volpicelli Paola,Breccia Massimo¹,Vozella Federico¹,Romano Angela¹,Montagna Chiara¹,Molica Matteo¹,Finsinger Paola¹,Carmosino Ida¹,Serrao Alessandra¹,Zacheo Irene¹,Santopietro Michelina¹,Salaroli Adriano¹,Alimena Giuliana¹

Affiliation:

1. Department of Cellular Biotechnologies and Hematology; University “La Sapienza” of Rome; Rome Italy

Publisher

Wiley

Subject

Hematology

Reference17 articles.

1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia;Druker;N Engl J Med,2001

2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

3. Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment;Hochhaus;Blood,2008

4. “Real-life” results of front-line treatment with imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia;Latagliata;Leuk Res,2010

5. Frontline imatinib treatment of chronic myeloid leukemia: No impact of age on outcome, a survey by the GIMEMA CML Working Party;Gugliotta;Blood,2011

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small-molecule α-lipoic acid targets ELK1 to balance human neutrophil and erythrocyte differentiation;Stem Cell Research & Therapy;2024-04-08

2. Comment on “Effect of imatinib treatment on renal anemia in chronic myeloid leukemia patients”;Journal of Oncology Pharmacy Practice;2023-09-24

3. Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated with Imatinib: A Evidence-based Meta-analysis;Current Reviews in Clinical and Experimental Pharmacology;2023-07

4. ULK1 inhibition promotes oxidative stress–induced differentiation and sensitizes leukemic stem cells to targeted therapy;Science Translational Medicine;2021-09-29

5. Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia;European Journal of Haematology;2020-05-22